Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar 25:8:599-604.
doi: 10.2147/OPTH.S58413. eCollection 2014.

Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients

Qasim Kadhim Farhood  1 , Sinan Mohammad Twfeeq  2
Affiliations

Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients

Qasim Kadhim Farhood et al. Clin Ophthalmol. .

Abstract

Background: This study examined the changes in short-term intraocular pressure (IOP) in a prospective series of patients undergoing intravitreal bevacizumab injection. The aim was to evaluate the frequency and predictive factors related to intraocular pressure (IOP) elevation in patients receiving intravitreal bevacizumab.

Patients and methods: This study included 52 patients with diabetic retinopathy between 28 to 75 years of age with a mean age of 51 years; 30 (58%) were females, and 22 (42%) were males. All patients received bevacizumab (1.25 mg/0.05 mL) injected intravitreally in a standard fashion between May 2012 to February 2013 in the AL-Jumhoury teaching hospital. IOP was measured at baseline, 5, 10, and 30 minutes after injection using Goldman applanation tonometry.

Statistics: Data were analyzed using the SPSS v.12.0 for windows. Basic, demographic, and clinical data were analyzed using means, proportions, and appropriate 95% confidence intervals (CIs).

Results: Most patients (85%) were diagnosed with proliferative diabetic retinopathy, while 15% presented with diabetic macular edema. The mean IOP values at baseline, 5, 10, and 30 minutes after injection were 14.0 mmHg (95% CI 13.4-14.7), 36.1 mmHg (95% CI 33.5-38.6), 25.7 mmHg (95% CI 23.8-27.5), and 15.5 mmHg (95% CI 12.4-16.51), respectively. Regression analysis showed a trend toward phakic patients having higher IOP at 30 minutes.

Conclusion: Intravitreal injection of bevacizumab is safe with respect to short-term IOP changes, as almost all IOP returned to a safe range (<25 mmHg) within 30 minutes. Elevated IOP 30 minutes after injection only occurs rarely, so routine prophylactic use of anti-glaucoma medication is not indicated.

Keywords: Goldmann applanation tonometry; bevacizumab; intraocular pressure; intravitreal injection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relationship between intraocular pressure and various time intervals after intravitreal injection.
See this image and copyright information in PMC

References

    1. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90(11):1344–1349. - PMC - PubMed
    1. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study) Retina. 2006;26(9):1006–1013. - PubMed
    1. Higashide T, Murotani E, Saito Y, Ohkubo S, Sugiyama K. Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol. 2012;250(4):603–610. - PubMed
    1. Mansour AM, Shahin M, Kofoed PK, Parodi MB, Shami M, Schwartz SG, Collaborative Anti-VEGF Ocular Vascular Complications Group Insight into 144 patients with ocular vascular events during VEGF antagonist injections. Clin Ophthalmol. 2012;6:343–363. - PMC - PubMed
    1. Manousaridis K, Talks J. Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease? Br J Ophthalmol. 2012;96(2):179–184. - PubMed

LinkOut - more resources